PL3415517T3 - Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika - Google Patents
Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznikaInfo
- Publication number
- PL3415517T3 PL3415517T3 PL18185835T PL18185835T PL3415517T3 PL 3415517 T3 PL3415517 T3 PL 3415517T3 PL 18185835 T PL18185835 T PL 18185835T PL 18185835 T PL18185835 T PL 18185835T PL 3415517 T3 PL3415517 T3 PL 3415517T3
- Authority
- PL
- Poland
- Prior art keywords
- methoxyurea
- methoxypyridazin
- tetrahydrothieno
- difluorobenzyl
- dimethylaminomethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012217679 | 2012-09-28 | ||
| PCT/JP2013/077013 WO2014051164A2 (en) | 2012-09-28 | 2013-09-27 | Production method of thienopyrimidine derivative |
| EP18185835.8A EP3415517B1 (en) | 2012-09-28 | 2013-09-27 | Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea |
| EP13779938.3A EP2900675B1 (en) | 2012-09-28 | 2013-09-27 | Production method of thienopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3415517T3 true PL3415517T3 (pl) | 2022-07-04 |
Family
ID=49448235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13779938T PL2900675T3 (pl) | 2012-09-28 | 2013-09-27 | Sposób wytwarzania pochodnej tienopirymidyny |
| PL18185835T PL3415517T3 (pl) | 2012-09-28 | 2013-09-27 | Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13779938T PL2900675T3 (pl) | 2012-09-28 | 2013-09-27 | Sposób wytwarzania pochodnej tienopirymidyny |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US9758528B2 (pl) |
| EP (3) | EP4119564A1 (pl) |
| JP (1) | JP6250564B2 (pl) |
| CN (3) | CN113372358B (pl) |
| AR (1) | AR092707A1 (pl) |
| CA (1) | CA2881132C (pl) |
| CY (2) | CY1121641T1 (pl) |
| DK (2) | DK3415517T3 (pl) |
| ES (2) | ES2913753T3 (pl) |
| HR (2) | HRP20220622T1 (pl) |
| HU (2) | HUE044048T2 (pl) |
| LT (2) | LT2900675T (pl) |
| PL (2) | PL2900675T3 (pl) |
| PT (2) | PT2900675T (pl) |
| RS (2) | RS58703B1 (pl) |
| SI (2) | SI2900675T1 (pl) |
| SM (2) | SMT202200255T1 (pl) |
| TR (1) | TR201906318T4 (pl) |
| TW (3) | TWI602819B (pl) |
| UY (1) | UY35058A (pl) |
| WO (1) | WO2014051164A2 (pl) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| SI3518932T1 (sl) | 2016-09-30 | 2025-03-31 | Takeda Pharmaceutical Company Limited | Zdravljenje raka prostate |
| WO2018086608A1 (zh) * | 2016-11-14 | 2018-05-17 | 江苏恒瑞医药股份有限公司 | 一种GnRH受体拮抗剂的结晶形式及其制备方法 |
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| CN107188855A (zh) * | 2017-07-14 | 2017-09-22 | 常州工程职业技术学院 | 一种3‑氨基‑6甲氧基哒嗪的制备方法 |
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| WO2019178304A1 (en) | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| EP3666776A1 (en) | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| EP3969455A4 (en) * | 2019-05-15 | 2023-07-05 | Dr. Reddy's Laboratories Limited | AMORPHOUS AND CRYSTALLINE FORMS OF RELUGOLIX |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| WO2021018105A1 (en) * | 2019-07-29 | 2021-02-04 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrimidinedione compounds and uses thereof |
| CA3145993A1 (en) * | 2019-08-02 | 2021-02-11 | Johnson Matthey Public Limited Company | Solid-state forms of relugolix |
| CN112321602A (zh) * | 2019-08-05 | 2021-02-05 | 苏州鹏旭医药科技有限公司 | 一种瑞卢戈利药物中间体的制备方法 |
| CN112390812A (zh) * | 2019-08-14 | 2021-02-23 | 苏州鹏旭医药科技有限公司 | 瑞卢戈利化合物的晶型和无定型固体及其制备方法 |
| CN112771052B (zh) * | 2019-08-21 | 2023-04-07 | 深圳仁泰医药科技有限公司 | 促性腺素释放激素拮抗剂的晶型及其制备方法和用途 |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| WO2021069700A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN112745304A (zh) * | 2019-10-29 | 2021-05-04 | 上海度德医药科技有限公司 | 一种Relugolix的制备方法及中间体化合物 |
| CN111423452B (zh) * | 2020-03-26 | 2023-08-22 | 江西青峰药业有限公司 | 瑞卢戈利的中间体及其制备方法和应用 |
| CN113444105A (zh) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | 一种Relugolix的制备方法 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN111574534B (zh) * | 2020-05-25 | 2021-06-04 | 东莞市东阳光新药研发有限公司 | 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| US11655256B1 (en) | 2020-11-06 | 2023-05-23 | Macfarlan Smith Limited | Processes for making a solid-state form of relugolix |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN112552312B (zh) * | 2020-12-07 | 2022-08-05 | 杭州科巢生物科技有限公司 | 一种瑞卢戈利或其盐的合成方法 |
| CN114685468A (zh) * | 2020-12-25 | 2022-07-01 | 成都硕德药业有限公司 | 用于治疗子宫肌瘤的药物的中间体化合物及其制备方法 |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| CN114907370B (zh) | 2021-02-10 | 2023-11-03 | 奥锐特药业(天津)有限公司 | 高纯度的噻吩并嘧啶化合物及其制备方法 |
| CN115073491A (zh) * | 2021-03-12 | 2022-09-20 | 上海医药工业研究院 | 一种瑞卢戈利中间体、其制备方法及其应用 |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| BR112023024454A2 (pt) * | 2021-06-15 | 2024-02-06 | Wigen Biomedicine Tech Shanghai Co Ltd | Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero |
| CN115594688B (zh) * | 2021-06-28 | 2023-11-17 | 成都倍特药业股份有限公司 | 瑞卢戈利中间体的制备方法 |
| WO2023042214A1 (en) | 2021-09-15 | 2023-03-23 | Cipla Limited | Solid state forms of relugolix |
| WO2023066941A1 (en) * | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN114230576A (zh) * | 2021-12-21 | 2022-03-25 | 伊诺药物研究(南京)有限公司 | 一种瑞卢戈利的制备方法 |
| WO2023119333A1 (en) * | 2021-12-25 | 2023-06-29 | Dr. Reddy’S Laboratories Limited | Process for preparation of relugolix and its intermediates |
| CN114409629B (zh) * | 2022-02-22 | 2023-12-29 | 浙江科聚生物医药有限公司 | 一种高纯度Relugolix关键中间体的制备方法及应用 |
| CN114790189B (zh) * | 2022-02-24 | 2023-06-09 | 海化生命(厦门)科技有限公司 | 瑞卢戈利中间体的制备方法 |
| CN114755320B (zh) * | 2022-03-17 | 2024-10-01 | 南京方生和医药科技有限公司 | 一种3-氨基-6-甲氧基哒嗪有关物质的检测方法 |
| IN202221021078A (pl) * | 2022-04-08 | 2023-10-13 | ||
| CN114621249B (zh) * | 2022-04-27 | 2024-01-26 | 江苏慧聚药业股份有限公司 | 瑞卢戈利关键中间体的制备 |
| CN119546611A (zh) | 2022-05-05 | 2025-02-28 | 台湾神隆股份有限公司 | 瑞卢戈利的制备工艺及其中间体 |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| CN115594689B (zh) * | 2022-07-14 | 2024-03-19 | 江西同和药业股份有限公司 | 一种瑞卢戈利中间体、一种瑞卢戈利的合成方法 |
| CN114989134B (zh) * | 2022-07-14 | 2023-11-14 | 江西同和药业股份有限公司 | 一种噻吩类化合物及其制备方法与应用 |
| CN115417883B (zh) * | 2022-09-16 | 2024-08-27 | 浙江科聚生物医药有限公司 | 一种瑞卢戈利的晶型及其制备方法 |
| WO2024069492A1 (en) | 2022-09-29 | 2024-04-04 | Macfarlan Smith Limited | Processes for the preparation and manufacture of relugolix |
| CN115650950A (zh) * | 2022-11-03 | 2023-01-31 | 江西同和药业股份有限公司 | 一种瑞卢戈利中间体及其制备方法以及一种酰胺缩合方法 |
| WO2024126674A1 (en) | 2022-12-15 | 2024-06-20 | Medichem, S.A. | Process for the preparation of relugolix |
| CN115650965B (zh) * | 2022-12-26 | 2023-03-31 | 南京威凯尔生物医药科技有限公司 | 一种瑞卢戈利关键中间体的制备方法 |
| WO2025037218A1 (en) * | 2023-08-11 | 2025-02-20 | Glenmark Life Sciences Limited | Crystalline solvate of relugolix and a process for its preparation |
| CN117327091B (zh) * | 2023-09-28 | 2026-06-05 | 浙江天宇药业股份有限公司 | 一种瑞卢戈利的合成方法 |
| CN119859136A (zh) * | 2023-10-19 | 2025-04-22 | 诚达药业股份有限公司 | 一种瑞卢戈利关键中间体化合物g及其制备方法 |
| CN119859135B (zh) * | 2023-10-19 | 2025-12-02 | 浙江工业大学 | 一种瑞卢戈利中间体及其制备方法 |
| WO2025127790A1 (ko) | 2023-12-12 | 2025-06-19 | 주식회사 와이에스생명과학 | 렐루골릭스의 제조방법 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5116436B1 (pl) * | 1971-05-31 | 1976-05-24 | ||
| EP0237289A3 (en) | 1986-03-14 | 1988-07-27 | Takeda Chemical Industries, Ltd. | Pyrazolo [3,4-d] pyrimidine derivatives, their production and use |
| JP2859791B2 (ja) | 1992-01-31 | 1999-02-24 | 吉富製薬株式会社 | ４−ブロモメチルビフェニル化合物の製造法 |
| US5312958A (en) | 1992-01-31 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Process for producing 4-bromomethylbiphenyl compounds |
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| JPH10298156A (ja) | 1997-04-28 | 1998-11-10 | Nippon Nohyaku Co Ltd | 置換ハロメチルフェニルカルバミド酸エステル類の製造方法 |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| US6849738B2 (en) | 2000-02-29 | 2005-02-01 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| JP2001316391A (ja) * | 2000-02-29 | 2001-11-13 | Takeda Chem Ind Ltd | チエノピリミジン誘導体の製造法 |
| GB2361917A (en) * | 2000-05-04 | 2001-11-07 | Astrazeneca Ab | Novel thieno[2,3-d]pyrimidinediones |
| JP2002068044A (ja) | 2000-09-04 | 2002-03-08 | Yamaha Motor Co Ltd | 自動二輪車用ハンドルシート |
| JP2002088044A (ja) * | 2000-09-14 | 2002-03-27 | Sumitomo Seika Chem Co Ltd | ４’−ブロモメチル−２−シアノビフェニルの製造方法 |
| DE60207280T2 (de) | 2001-09-04 | 2006-05-18 | Akzo Nobel N.V. | GLYCINSUBSTITUIERTE THIENO[2,3-d]PYRIMIDINE MIT KOMBINIERTER LH- UND FSH-AGONISTISCHER WIRKUNG |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| EP1479684A4 (en) * | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME |
| CN1326569C (zh) | 2002-02-26 | 2007-07-18 | 阿斯特拉曾尼卡有限公司 | 含有水溶性纤维素衍生物的iressa药物制剂 |
| EP1579387A1 (en) | 2002-12-20 | 2005-09-28 | Koninklijke Philips Electronics N.V. | Enhancing video images depending on prior image enhancements |
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| WO2006014647A2 (en) * | 2004-07-21 | 2006-02-09 | Athersys, Inc. | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof |
| EP1806053A1 (en) | 2004-10-25 | 2007-07-11 | Nihon Nohyaku Co., Ltd. | Herbicide compositions for upland farming and control method |
| KR20080041662A (ko) * | 2005-07-22 | 2008-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 조기 배란 예방제 |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| US20110172249A1 (en) | 2008-09-03 | 2011-07-14 | Takeda Pharmaceutical Company Limted | Method for improving absorbability of preparation, and preparation having improved absorbability |
| AU2012221800B2 (en) * | 2011-02-23 | 2016-10-27 | Lupin Limited | Heteroaryl derivatives as alpha7 nAChR modulators |
| JP2012217679A (ja) | 2011-04-11 | 2012-11-12 | Okumura Yu-Ki Co Ltd | パチンコ遊技機 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| EP4223298A3 (en) | 2013-03-15 | 2023-08-16 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| AU2015308987B2 (en) | 2014-08-26 | 2021-02-18 | Kaass Discovery As | Methods, agents and compositions for treatment of inflammatory conditions |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| SI3518932T1 (sl) | 2016-09-30 | 2025-03-31 | Takeda Pharmaceutical Company Limited | Zdravljenje raka prostate |
-
2013
- 2013-09-27 SM SM20220255T patent/SMT202200255T1/it unknown
- 2013-09-27 EP EP22168256.0A patent/EP4119564A1/en active Pending
- 2013-09-27 LT LTEP13779938.3T patent/LT2900675T/lt unknown
- 2013-09-27 PL PL13779938T patent/PL2900675T3/pl unknown
- 2013-09-27 HU HUE13779938A patent/HUE044048T2/hu unknown
- 2013-09-27 JP JP2014557263A patent/JP6250564B2/ja active Active
- 2013-09-27 TR TR2019/06318T patent/TR201906318T4/tr unknown
- 2013-09-27 PL PL18185835T patent/PL3415517T3/pl unknown
- 2013-09-27 PT PT13779938T patent/PT2900675T/pt unknown
- 2013-09-27 RS RS20190473A patent/RS58703B1/sr unknown
- 2013-09-27 SI SI201331414T patent/SI2900675T1/sl unknown
- 2013-09-27 CA CA2881132A patent/CA2881132C/en not_active Expired - Fee Related
- 2013-09-27 US US14/432,188 patent/US9758528B2/en active Active
- 2013-09-27 UY UY0001035058A patent/UY35058A/es not_active Application Discontinuation
- 2013-09-27 HR HRP20220622TT patent/HRP20220622T1/hr unknown
- 2013-09-27 PT PT181858358T patent/PT3415517T/pt unknown
- 2013-09-27 TW TW102134983A patent/TWI602819B/zh active
- 2013-09-27 EP EP13779938.3A patent/EP2900675B1/en active Active
- 2013-09-27 WO PCT/JP2013/077013 patent/WO2014051164A2/en not_active Ceased
- 2013-09-27 CN CN202110609164.4A patent/CN113372358B/zh active Active
- 2013-09-27 HR HRP20190729TT patent/HRP20190729T1/hr unknown
- 2013-09-27 RS RS20220449A patent/RS63199B1/sr unknown
- 2013-09-27 HU HUE18185835A patent/HUE059077T2/hu unknown
- 2013-09-27 AR ARP130103480A patent/AR092707A1/es unknown
- 2013-09-27 ES ES18185835T patent/ES2913753T3/es active Active
- 2013-09-27 LT LTEP18185835.8T patent/LT3415517T/lt unknown
- 2013-09-27 CN CN201811130716.8A patent/CN109053766B/zh active Active
- 2013-09-27 SI SI201331988T patent/SI3415517T1/sl unknown
- 2013-09-27 CN CN201380051107.2A patent/CN104703992B/zh active Active
- 2013-09-27 ES ES13779938T patent/ES2724206T3/es active Active
- 2013-09-27 TW TW107136006A patent/TWI663171B/zh active
- 2013-09-27 DK DK18185835.8T patent/DK3415517T3/da active
- 2013-09-27 TW TW106130632A patent/TWI641611B/zh active
- 2013-09-27 DK DK13779938.3T patent/DK2900675T3/da active
- 2013-09-27 EP EP18185835.8A patent/EP3415517B1/en active Active
- 2013-09-27 SM SM20190255T patent/SMT201900255T1/it unknown
-
2017
- 2017-04-07 US US15/481,505 patent/US10150778B2/en active Active
-
2018
- 2018-07-12 US US16/034,002 patent/US10464945B2/en active Active
- 2018-08-29 US US16/116,804 patent/US10544160B2/en active Active
-
2019
- 2019-05-21 CY CY20191100544T patent/CY1121641T1/el unknown
- 2019-12-11 US US16/710,390 patent/US11053257B2/en active Active
-
2021
- 2021-06-16 US US17/349,584 patent/US11731983B2/en active Active
-
2022
- 2022-03-14 US US17/694,635 patent/US11795178B2/en active Active
- 2022-05-19 CY CY20221100341T patent/CY1125151T1/el unknown
-
2023
- 2023-03-15 US US18/121,886 patent/US12180224B2/en active Active
-
2024
- 2024-10-25 US US18/927,346 patent/US12325714B2/en active Active
-
2025
- 2025-05-07 US US19/201,728 patent/US20250368660A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202200255T1 (it) | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea | |
| ZA201407632B (en) | Triazolone compounds as mpges-1 inhibitors | |
| IL242285A (en) | Compounds 4-methoxy-n3- (pyrimidine-2-ram) benzene-3, 1-substituted diamine and their salts | |
| HUE039666T2 (hu) | Vízipipa-hõkezelõ tartozék | |
| PL2836072T3 (pl) | Kompozycja chwastobójcza zawierająca związek uracylowy jako składnik czynny | |
| ZA201208125B (en) | Pyrazole compounds as jak inhibitors | |
| ZA201408644B (en) | Nitrogenated heterocyclic compound | |
| GB201012105D0 (en) | Novel pyrimidine compounds | |
| ZA201309733B (en) | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| IL236326A0 (en) | Analogues of modified bicyclic methoxypyrazole, preparations containing them and their uses | |
| EP2936401A4 (en) | MANAGEMENT OF INFORMATION TECHNOLOGY SERVICES | |
| IL233800A0 (en) | Pyrimidine compounds are fungicidal | |
| GB201120644D0 (en) | Herbicidal uses of compounds | |
| IL233825A0 (en) | Use of h1-indazole-3-carboxamide compounds as glycogen synthase kinase 3 inhibitors in the cell | |
| IL226920A (en) | Pyrazole compounds as antagonists of crth2 | |
| IL233799A0 (en) | Pyrimidine compounds are fungicidal | |
| SI2608789T2 (sl) | Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina | |
| ZA201303800B (en) | Pyrazole compounds | |
| ZA201302996B (en) | Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate | |
| HK1188394A (en) | Formulations of phenyl uracil compounds | |
| AP2014008073A0 (en) | Nitrogenated heterocyclic compound | |
| IL218571A0 (en) | Resolution of 1 - (4 - methoxybenzyl) octahydro - isoquinoline | |
| GB201219148D0 (en) | Herbicidal compounds |